No Data
Express News | Gilead : Mizuho Raises Target Price to $117 From $100
Notable Healthcare Headlines for the Week: Gilead, CVS Health, Sanofi in Focus
Gilead and Vertex Pharma Named Among Biotech's Tariff Safe Havens
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $117
Gilead Sciences (GILD) Gets a Buy From Mizuho Securities
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110
小粉红的papa : It seems that not many people pay attention to biopharmaceutical Stocks, it's quite niche.
Everyone only invests in Technology Stocks.